Donanemab for treating early symptomatic Alzheimer’s disease

Donanemab is currently in clinical development for the treatment of early Alzheimer’s disease
(AD). AD is a progressive neurological disease which is caused by loss of function and death of
neurones in the brain. It is the most common type of dementia. One of the early symptoms of AD
is mild cognitive impairment where a person may have difficulty with memory, reasoning,
attention. The difficulties are significant enough to be noticed by the patient and their family or
friends but not enough to affect their ability to carry out some everyday activities. Current
treatment options for AD aim to relieve the symptoms (including cognitive impairment) rather
than stop progression of the disease.